ANN SURG ONCOL 润色咨询

ANNALS OF SURGICAL ONCOLOGY

出版年份:1994 年文章数:9919 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:6.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2022-08-30 ms8000002097933533

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2022-10-08 ms4000000706958642

    审稿速度:12.0 | 投稿命中率:5.0
    偏重的研究方向:胰腺癌
    经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家
    2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件
    2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)
    2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天
    2022-10-7接受
    总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下
    最后,也祝愿其他人一击即中

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2022-09-08 VirusLD50

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。
    EJSO、ASO各一篇 哈哈

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2022-10-29 0春夏秋冬0

    这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2021-06-04 12200887m48(暂无昵称)

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。

    12

    展开12条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2022-08-17 120b8a34m98暂无昵称

    请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2020-08-19 牵牛花开

    请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?

    4

    展开4条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2021-03-26 六公子

    审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0
    偏重的研究方向:胸外科;肿瘤学;肺癌
    经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。

    16

    展开16条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2022-06-02 ms4000000210206098

    收个案吗

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1242107, encodeId=4b65124210e56, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:非常不建议投这个杂志,投稿的时候要先交50美金的审稿费,投稿程序搞得巨繁琐,审稿还非常慢,从投稿到first decision拒稿等了整整两个月,两个审稿人,一个还给了一些建设性意见,另一个感觉完全就是凑数的,赶时间的朋友尤其要避开这个坑啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5218206857, createdName=ms8000002097933533, createdTime=Tue Aug 30 19:37:01 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092439, encodeId=bf6e2092439fd, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:胰腺癌<br>经验分享:本人刚刚接收了一篇临床论著,过程非常艰辛,和大家分享一下经验,希望可以帮助到大家<br>2022-3-17投稿,过程很复杂,需要做一个PPT和审稿费50美金,每个作者都要填写确认邮件<br>2022-6-6给了大修,一个审稿人意见不多比较满意,一个审稿人意见很多,30+条,我大概改了2周多,反复调整,然后写了一个3000字的回答信(其实对方的意见很中肯,确实对我来说很受用)<br>2022-8-8再次给了大修,不过第一个审稿人满意了,没提意见,第二审稿人提了5个意见,还算和善,大概修改了10天<br>2022-10-7接受<br>总结:我觉这个杂志真的很严谨,很抓细节,他们的意见非常中肯,让我学到了很多,就是过程太慢了,整了7个多月,因为每次审稿人都看得非常仔细,恨不得标点符号都要研究一下<br>最后,也祝愿其他人一击即中<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45145480404, createdName=ms4000000706958642, createdTime=Sat Oct 08 10:23:15 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247815, encodeId=12fd124e815a1, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:刚刚接收,投稿一个月左右Major Revision with No Acceptance Implied,修回后1个月左右直接接收。<br>EJSO、ASO各一篇 哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9df2165707, createdName=VirusLD50, createdTime=Thu Sep 08 06:47:19 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097366, encodeId=b34f209e3665f, content=这个杂志的Visual Abstract 和 ASO Author Reflection 也是当做article在刊登么?不会拉低杂志的影响因子吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Sat Oct 29 21:38:23 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:胸部肿瘤临床文章 4.17投稿 5.5意见返回来(小修) 5.17投回去 6.2接收,还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239331, encodeId=4c7e1239331d1, content=请问大神 刚刚投稿了 提交过程 为啥没有要求付审稿费的窗口啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb42202032, createdName=120b8a34m98暂无昵称, createdTime=Wed Aug 17 17:37:46 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810718, encodeId=79fb810e1888, content=请问各位大侠,我投稿成功后就出现了两个编辑的名字,下面就有“Under Review”,但是“Under Review”前面的按钮是灰色的,请问大家伙知道这个是已经送外审了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Aug 19 15:06:22 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951375, encodeId=b4a39513e5e7, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:100.0<br>偏重的研究方向:胸外科;肿瘤学;肺癌<br>经验分享:去年十一月底投稿,今年一月初收到major revision的decision letter,给了11条非常中肯的意见,花了20天修改resubmit后过了一月收到minor revision的decision letter,给了两条意见,花了10天修改提交后只过了8天就再次收到了minor revision的decision letter,又提了两条意见,花了9天再次修改提交后,只过了4天就accept了。这是我第一次投SCI,前后经历了一次大修,两次小修,一共花了三月多不到四月的时间。杂志审稿非常迅速,给编辑发的邮件回复得也很及时,reviewer每次的意见也非常中肯,没有版面费,accept后还被邀请写Author Reflections,非常好的一本杂志。非常有收获和愉快的一次投稿经历。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/23/3d12259d3d39e7fcfecf6d6df24de45a.jpg, createdBy=72c62363340, createdName=六公子, createdTime=Fri Mar 26 13:15:36 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223985, encodeId=8b1912239859b, content=收个案吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ed16157580, createdName=ms4000000210206098, createdTime=Thu Jun 02 08:22:47 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889215, encodeId=7b2788921583, content=审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0<br>偏重的研究方向:胃肠外科;肿瘤<br>经验分享:贴两个今年投稿的status,其中第二个还在返修中。<br>1# <br>2020-7-28 submitted<br>30-Jul-2020 Under Review<br>14-Aug-2020 Reject<br><br>2#<br>16-Aug-2020 submitted<br>17-Aug-2020 Under Review<br>25-Aug-2020 Major Revision with No Acceptance Implied, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=mkong82, createdTime=Tue Sep 29 15:00:04 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2020-09-29 mkong82

    审稿速度:1.0 | 投稿命中率:50.0 | 审稿费用:50.0
    偏重的研究方向:胃肠外科;肿瘤
    经验分享:贴两个今年投稿的status,其中第二个还在返修中。
    1#
    2020-7-28 submitted
    30-Jul-2020 Under Review
    14-Aug-2020 Reject

    2#
    16-Aug-2020 submitted
    17-Aug-2020 Under Review
    25-Aug-2020 Major Revision with No Acceptance Implied

    6

    展开6条回复
共204条页码: 2/21页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分